Ken Griffin Eye Point Pharmaceuticals, Inc. Put Options Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2024 May 15, 2024	BUY	$19.93 - $29.71 $839,053 - $1.25 Million	42,100 Added 92.73%	87,500 $1.81 Million
Q4 2023 Feb 14, 2024	BUY	$5.71 - $24.13 $93,073 - $393,319	16,300 Added 56.01%	45,400 $1.05 Million
Q3 2023 Nov 14, 2023	BUY	$7.99 - $15.36 $174,182 - $334,848	21,800 Added 298.63%	29,100 $232,000
Q2 2023 Aug 14, 2023	BUY	$3.03 - $9.0 $13,332 - $39,600	4,400 Added 151.72%	7,300 $63,000
Q1 2023 May 15, 2023	SELL	$2.28 - $5.04 $7,067 - $15,624	-3,100 Reduced 51.67%	2,900 $8,000

Q4 2022 Feb 14, 2023	BUY	$2.37 - $7.2 $14,220 - $43,200	6,000 New	6,000 $21,000

176

53.9M

764K

1.57M

Ticker EYPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,072,200
Market Cap $296M
Description
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.